Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SpyGlass PharmaSGP -0.59%12 Cash Ratio is 24.82 as of Jun. 2026, which is 39% above its 10-year median of 17.86. GuruFocus rates SGP with a GF Score™ of 12/100. Among 1,379 Biotechnology companies, SpyGlass Pharma ranks better than 98.04% on this metric.
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
SpyGlass Pharma Cash Ratio Related Terms
SpyGlass Pharma Cash Ratio Historical Data
* Premium members only.
The historical data trend for SpyGlass Pharma's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, SpyGlass Pharma's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SpyGlass Pharma Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SpyGlass Pharma's Cash Ratio distribution charts can be found below:
* The bar in red indicates where SpyGlass Pharma's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SpyGlass Pharma (SGP) has a Cash Ratio of 24.82 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on SpyGlass Pharma and its competitors. This is 39% above median its historical median of 17.86. Over the past decade, SpyGlass Pharma's Cash Ratio has ranged from 2.09 to 37.65. According to the industry distribution chart, SpyGlass Pharma ranks #27 out of 1379 companies in the Biotechnology industry, placing it in the top 2%.
Is SpyGlass Pharma's Cash Ratio too high?
SpyGlass Pharma's current Cash Ratio of 24.82 is 39% above median its 10-year median of 17.86. Over the past 10 years, this metric has ranged from a low of 2.09 to a high of 37.65. The Biotechnology industry median Cash Ratio is 2.93. SpyGlass Pharma's value of 24.82 is 747.1% above this industry median. Based on the distribution chart, SpyGlass Pharma ranks #27 out of 1379 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, SpyGlass Pharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does SpyGlass Pharma's Cash Ratio compare to RIGL and NGNE?
According to the Biotechnology industry distribution chart, SpyGlass Pharma ranks #27 out of 1379 companies for Cash Ratio. This places SpyGlass Pharma in the top 2% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.93. SpyGlass Pharma's value of 24.82 is 747.1% above this benchmark. Historically, SpyGlass Pharma's own Cash Ratio has ranged from 2.09 to 37.65 over the past decade. While the company's 10-year median is 17.86 vs. the industry median of 2.93, SpyGlass Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,379 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SpyGlass Pharma's current Cash Ratio of 24.82 is 747.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on SpyGlass Pharma and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SpyGlass Pharma's current Cash Ratio is 24.82, which is 39% above median its own 10-year median of 17.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SpyGlass Pharma stock overvalued right now?
SpyGlass Pharma (SGP) has a current Cash Ratio of 24.82. The current Cash Ratio is 24.82, which is 39% above median its 10-year median of 17.86 and 747.1% above the Biotechnology industry median of 2.93. SpyGlass Pharma's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For SpyGlass Pharma (SGP), the current Cash Ratio is 24.82 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
12GF Score
Get the complete analysis for SGP
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGP has been successfully added to your 
